NCT03841110 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT03829436 TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers Status COMPLETED Phase PHASE1
NCT03827837 Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors Status UNKNOWN Phase PHASE2
NCT03809013 A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer Status COMPLETED Phase PHASE2
NCT03788746 Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma Status COMPLETED Phase N/A
NCT03782207 A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice Status ACTIVE_NOT_RECRUITING Phase N/A
NCT03758781 IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Status COMPLETED Phase PHASE1
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Status COMPLETED Phase PHASE1
NCT03737123 Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Status TERMINATED Phase PHASE2
NCT03735680 A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer Status COMPLETED Phase PHASE2
NCT03689192 Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors Status COMPLETED Phase PHASE1
NCT03676946 A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Locally Advanced and Metastatic Urothelial Carcinoma Status UNKNOWN Phase PHASE1/PHASE2
NCT03665285 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT03658304 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma Status COMPLETED Phase PHASE2
NCT03652077 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Status COMPLETED Phase PHASE1
NCT03636256 Evaluation of NanoDoce® in Participants With Urothelial Carcinoma Status COMPLETED Phase PHASE1/PHASE2